Literature DB >> 26945868

Angiopoietin-1 and -2 as markers for disease severity in hemolytic uremic syndrome induced by enterohemorrhagic Escherichia coli.

Masaki Shimizu1, Natsumi Inoue2, Mondo Kuroda2, Mao Mizuta2, Naotoshi Sugimoto3, Hisashi Kaneda4, Kazuhide Ohta5, Akihiro Yachie2.   

Abstract

BACKGROUND: Angiopoietin (Ang)-1 and -2 play important roles in maintaining vascular homeostasis. This study aimed to assess the roles of angiopoietin (Ang)-1 and -2 and to investigate the clinical significance of their serum levels in patients with hemolytic uremic syndrome (HUS) induced by enterohemorrhagic Escherichia coli (EHEC).
METHODS: Twenty patients with HUS and 15 healthy controls were studied. Serum Ang-1 and Ang-2 levels were quantified using enzyme-linked immunosorbent assay. The results were compared with the clinical features of HUS.
RESULTS: During the HUS phase, serum Ang-1 levels were significantly decreased, whereas serum Ang-2 levels and the Ang-2/Ang-1 ratio were significantly elevated. Compared with patients without encephalopathy, serum Ang-2 levels and Ang-2/Ang-1 ratio were significantly elevated in patients with encephalopathy. Patients with HUS and serum Ang-2 levels of >7061 pg/mL or Ang2/Ang1 ratios of >2.29 were at high risk of encephalopathy. Serum Ang-1 levels were significantly decreased in patients in the pre-HUS phase compared with those in healthy controls.
CONCLUSION: Disruption of homeostasis of vascular endothelial function by Ang-1 and -2 may be closely associated with the development of HUS. Serum Ang-1 and -2 levels and the Ang-2/Ang-1 ratio may be promising indicators of disease activity in HUS and the development of encephalopathy.

Entities:  

Keywords:  Angiopoietin-1; Angiopoietin-2; Enterohemorrhagic Escherichia coli; Hemolytic uremic syndrome

Mesh:

Substances:

Year:  2016        PMID: 26945868     DOI: 10.1007/s10157-016-1254-z

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  33 in total

1.  Interleukin-6 promotes destabilized angiogenesis by modulating angiopoietin expression in rheumatoid arthritis.

Authors:  Ken Kayakabe; Takashi Kuroiwa; Noriyuki Sakurai; Hidekazu Ikeuchi; Anastasie Tshilela Kadiombo; Toru Sakairi; Takayuki Matsumoto; Akito Maeshima; Keiju Hiromura; Yoshihisa Nojima
Journal:  Rheumatology (Oxford)       Date:  2012-05-16       Impact factor: 7.580

Review 2.  Angiopoietins: a link between angiogenesis and inflammation.

Authors:  Ulrike Fiedler; Hellmut G Augustin
Journal:  Trends Immunol       Date:  2006-10-12       Impact factor: 16.687

3.  Neurological complications of hemolytic-uremic syndrome.

Authors:  J S Hahn; P L Havens; J J Higgins; P P O'Rourke; J A Estroff; R Strand
Journal:  J Child Neurol       Date:  1989-04       Impact factor: 1.987

4.  The hemolytic-uremic syndrome.

Authors:  C A Gianantonio; M Vitacco; F Mendilaharzu; G E Gallo; E T Sojo
Journal:  Nephron       Date:  1973       Impact factor: 2.847

Review 5.  Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome.

Authors:  R L Siegler
Journal:  J Pediatr       Date:  1994-10       Impact factor: 4.406

6.  Soluble tumor necrosis factor receptor 1 and tissue inhibitor of metalloproteinase-1 in hemolytic uremic syndrome with encephalopathy.

Authors:  Masahiro Shiraishi; Takashi Ichiyama; Takeshi Matsushige; Takuma Iwaki; Kuniaki Iyoda; Ken Fukuda; Haruyuki Makata; Tomoyo Matsubara; Susumu Furukawa
Journal:  J Neuroimmunol       Date:  2008-04-14       Impact factor: 3.478

7.  Cytokine profiles of patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome.

Authors:  Masaki Shimizu; Mondo Kuroda; Natsumi Sakashita; Michio Konishi; Hisashi Kaneda; Noboru Igarashi; Junya Yamahana; Hiromichi Taneichi; Hirokazu Kanegane; Mika Ito; Shigeru Saito; Kazuhide Ohta; Takumi Taniguchi; Kengo Furuichi; Takashi Wada; Masaru Nakagawa; Hitoshi Yokoyama; Akihiro Yachie
Journal:  Cytokine       Date:  2012-08-25       Impact factor: 3.861

8.  Role of vascular endothelial growth factor and angiopoietin 1 in renal injury in hemolytic uremic syndrome.

Authors:  Shinichiro Ohara; Yukihiko Kawasaki; Yusaku Abe; Masahiro Watanabe; Atsushi Ono; Kazuhide Suyama; Koichi Hashimoto; Takashi Honda; Junzo Suzuki; Mitsuaki Hosoya
Journal:  Am J Nephrol       Date:  2012-11-17       Impact factor: 3.754

Review 9.  Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome.

Authors:  E G Gallo; C A Gianantonio
Journal:  Pediatr Nephrol       Date:  1995-02       Impact factor: 3.714

10.  Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients.

Authors:  Philipp Kümpers; Alexander Lukasz; Sascha David; Rüdiger Horn; Carsten Hafer; Robert Faulhaber-Walter; Danilo Fliser; Hermann Haller; Jan T Kielstein
Journal:  Crit Care       Date:  2008-11-21       Impact factor: 9.097

View more
  3 in total

1.  Cerebral Hemodynamics in Patients with Hemolytic Uremic Syndrome Assessed by Susceptibility Weighted Imaging and Four-Dimensional Non-Contrast MR Angiography.

Authors:  Ulrike Löbel; Nils Daniel Forkert; Peter Schmitt; Thorsten Dohrmann; Maria Schroeder; Tim Magnus; Stefan Kluge; Christina Weiler-Normann; Xiaoming Bi; Jens Fiehler; Jan Sedlacik
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

2.  Serum insulin-like growth factor-binding protein 2 levels as an indicator for disease severity in enterohemorrhagic Escherichia coli induced hemolytic uremic syndrome.

Authors:  Yuko Tasaki; Natsumi Inoue; Masaki Shimizu; Naotoshi Sugimoto; Sayaka Ishikawa; Mao Mizuta; Tadafumi Yokoyama; Mondo Kuroda; Kazuhide Ohta; Akihiro Yachie; Taizo Wada
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

3.  Circulating level of Angiopoietin-2 is associated with acute kidney injury in coronavirus disease 2019 (COVID-19).

Authors:  Brandon Michael Henry; Maria Helena Santos de Oliveira; Isaac Cheruiyot; Justin L Benoit; David S Cooper; Giuseppe Lippi; Timothy D Le Cras; Stefanie W Benoit
Journal:  Angiogenesis       Date:  2021-03-23       Impact factor: 10.658

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.